PanTera Series A 2024

TLDR

PanTera raised EUR 134M in total funding in September 2024, led by EQT Life Sciences with a EUR 93M anchor investment, at a valuation of EUR 280M, the largest Belgian life sciences funding round on record.

Overview

PanTera's EUR 134M raise was led by EQT Life Sciences, one of Europe's most prominent healthcare-focused investment arms within the EQT Group. The EUR 93M anchor from EQT Life Sciences formed the core of a EUR 134M total raise, implying additional co-investors.

The company was valued at EUR 280M at the time of the round, reflecting the strategic importance of its actinium-225 production facility in Mol, which sits within SCK CEN, Belgium's national nuclear research center.

The round is the largest single life sciences funding event in Belgian history, reflecting both the global shortage of actinium-225 and PanTera's unique position as one of the few entities in the world capable of producing the isotope at pharmaceutical-grade scale.

Funding History

• Growth round, EUR 134M (EUR 93M EQT Life Sciences lead), 2024, valuation EUR 280M